Conivaptan

Evidence Level: L4

Predicted Indications: 7

Conivaptan

Pharmacist Assessment Report

Conivaptan: From Hyponatremia (Injectable Vasopressin Antagonist) to Pulmonary Hypertension

One-Sentence Summary

Conivaptan is an injectable vasopressin V1A/V2 receptor antagonist, marketed in India under the brand Hyponat 20 mg Injection. The TxGNN model predicts it may be effective for pulmonary hypertension, but the supporting evidence is thin: 1 clinical trial (withdrawn, no participants enrolled) and 1 review article on hyponatremia in heart failure. At this stage the prediction is a research question, not an evidence-backed indication.

Quick Overview

Item	Content
Original Indication	Not stated in the Indian license data (conivaptan is generally used for hyponatremia)
Predicted New Indication	Pulmonary hypertension
TxGNN Prediction Score	0.9952
Evidence Level	L4 (preclinical and mechanistic support only; the one trial was withdrawn)
India Market Status	Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data
Number of Listed Products	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Conivaptan is a dual vasopressin V1A/V2 receptor antagonist. Blocking V2 receptors promotes aquaresis (excretion of free water without major electrolyte loss), which may help control body volume. Blocking V1A receptors may reduce vasopressin-driven vasoconstriction.

In pulmonary arterial hypertension with right ventricular failure, sodium and water retention is driven partly by secondary hyperaldosteronism and non-osmotic vasopressin release. A V2 antagonist could in theory ease this volume overload. The link is plausible but indirect. It mainly supports managing hyponatremia and congestion in heart failure, not treating the pulmonary vascular disease itself.

Detailed mechanism of action data was not available in the data compiled for this report. The mechanistic description above is based on the known pharmacology of conivaptan.

Other model predictions (migraine disorder, Prinzmetal angina, migraine with brainstem aura, kyphoscoliotic heart disease, peripheral arterial disease, peripheral vascular disease) have no supporting trials, or only unrelated literature. They are not developed further here.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00811486	NA	Withdrawn	0	Planned study of body volume regulation in pulmonary arterial hypertension with right ventricular failure, using a mineralocorticoid antagonist plus a V2 antagonist. Withdrawn with no participants, so it produced no efficacy or safety data.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30843491	2019	Review	Current Cardiology Reviews	Pathogenesis and management of hyponatremia in heart failure. Relevant to volume handling, not directly to pulmonary hypertension.
15847853	2005	Review	American Journal of Cardiology	Treatments for hyponatremia in congestive heart failure. Linked to the peripheral arterial disease prediction and does not address vascular disease.
10448882	1999	Preclinical	European Journal of Pharmacology	Cardiovascular and renal effects of conivaptan (YM087) in dogs with pacing-induced heart failure. Linked to the peripheral vascular disease prediction. Pharmacology and hemodynamics only.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
104711	Hyponat 20mg Injection (Zydus Cadila)	Vial of 4 ml injection	Not stated in the license data

Safety Considerations

Drug Interactions: The interaction screen identified 180 potential interacting drugs. Examples of Major interactions include loperamide, triamcinolone, budesonide, clarithromycin, cisapride, eliglustat, and naloxegol. Moderate interactions include rabeprazole, hydrocortisone, dexamethasone, betamethasone, aprepitant, granisetron, miconazole, eluxadoline, and naldemedine. Many of these (for example clarithromycin) are consistent with CYP3A4-related effects, but the data compiled for this report do not specify the mechanism.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The high TxGNN score (0.9952) is a computational prediction. The mechanistic link is plausible but indirect, so there is no clinical evidence for pulmonary hypertension.

Review correction (2026-10-31): Originally stated: “The high TxGNN score (0.9952) is a computational prediction. The only trial was withdrawn without enrolling anyone, and the literature consists of reviews on heart-failure hyponatremia and animal pharmacology.” Removed: it said the product records were cancelled, discontinued, or not current, which did not match the Indian medicine data (the Indian Medicine Dataset as of 2026-10-31). The data list 1 product record for this drug, 1 current; the Quick Overview and the table under India Market Information show the current figures. Source: Indian Medicine Dataset.

To proceed, the following is needed:

Package insert warnings, contraindications, and approved indication text for Hyponat 20 mg Injection (currently missing and blocking safety screening)
Detailed mechanism of action data
Clinical data in pulmonary hypertension, such as a well-designed pilot or Phase 2 study, especially in right heart failure with volume overload
Evaluation of the clinical relevance of the many Major drug interactions
Assessment of whether the injectable-only route suits the intended use in pulmonary hypertension

Review Log

Below is the review log for this page: statements checked against official Indian medicine data (the Indian Medicine Dataset used by this site). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.

Review date	Item	Action	Source
2026-10-31	Removed: “The only trial was withdrawn without enrolling anyone, and the literature consists of reviews on heart-failure hyponatremia and animal pharm”	Corrected	Indian Medicine Dataset

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.